Loading…

A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology

Patient-derived tumor xenograft (PDX)/organoid (PDO), driven by cancer stem cells (CSC), are considered the most predictive models for translational oncology. Large PDX collections reflective of patient populations have been created and used extensively to test various investigational therapies, inc...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2023-01, Vol.18 (1), p.e0279821
Main Authors: Xu, Xiaoxi, Kumari, Rajendra, Zhou, Jun, Chen, Jing, Mao, Binchen, Wang, Jingjing, Zheng, Meiling, Tu, Xiaolong, An, Xiaoyu, Chen, Xiaobo, Zhang, Likun, Tian, Xiaoli, Wang, Haojie, Dong, Xin, Bao, Zhengzheng, Guo, Sheng, Ouyang, Xuesong, Shang, Limei, Wang, Fei, Yan, Xuefei, Zhang, Rui, Vries, Robert G J, Clevers, Hans, Li, Qi-Xiang
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patient-derived tumor xenograft (PDX)/organoid (PDO), driven by cancer stem cells (CSC), are considered the most predictive models for translational oncology. Large PDX collections reflective of patient populations have been created and used extensively to test various investigational therapies, including population-trials as surrogate subjects in vivo. PDOs are recognized as in vitro surrogates for patients amenable for high-throughput screening (HTS). We have built a biobank of carcinoma PDX-derived organoids (PDXOs) by converting an existing PDX library and confirmed high degree of similarities between PDXOs and parental PDXs in genomics, histopathology and pharmacology, suggesting "biological equivalence or interchangeability" between the two. Here we demonstrate the applications of PDXO biobank for HTS "matrix" screening for both lead compounds and indications, immune cell co-cultures for immune-therapies and engineering enables in vitro/in vivo imaging. This large biobank of >550 matched pairs of PDXs/PDXOs across different cancers could become powerful tools for the future cancer drug discovery.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0279821